Drug to treat neurodegenerative diseases

13 Jun 2017

NanoLithium® (NP03) is a disease-modifying nano dose formulation of lithium citrate in an AONYS® reverse microemulsion. NP03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at doses two orders of magnitude lower than those used in currently marketed lithium specialties.
Studies on transgenic animal models of Alzheimer’s disease and Huntington’s disease have shown that NP03 has a disease-modifying therapeutic activity by inhibiting neuronal death and inducing the production of new neurons from neural stem cells.

Lithium is well known to interact with a number of targets including kinases, various enzymes, transcription factors and receptors involved notably in the homeostasis of neural cells.Lithium is both a stimulator of neurogenesis as well as a neuroprotectorand has accordingly been suggested as a drug for the treatment of several neurodegenerative diseases,notably Alzheimer’s and Huntington’s diseases.

See the paper here.